Request a quote
All products
Active Pharmaceutical IngredientsPharmaceutical IntermediatesVeterinary APIsPharmaceutical Packaging
Quality & compliance Resources About Contact
ENESFRRU
Request a quote

Meloxicam

4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide · CAS 71125-38-7

Veterinary USP / EP / Veterinary grade CoA per batchSDSMRL guidance note

The oxicam used across nearly every veterinary species, which means one API serves several registrations. Polymorph form and particle size are both specified because suspension injectables are sensitive to both.

Part of the veterinary anti-inflammatory line, mostly injectables where the salt form and the polymorph decide stability.

Identity

Catalogue no.BP-VET-011
CAS number71125-38-7
Molecular formulaC14H13N3O4S2
Molecular weight351.39 g/mol
HS code2934.99
Synonyms4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
Product lineVeterinary APIs
CategoryVeterinary Anti-inflammatories

Release specification

Catalogue standard below. For a supply agreement we release against your dossier specification; send it with the enquiry and the CoA will be built around it.

ParameterSpecification
Assay99.0–101.0%
Related substancesAny unspecified impurity ≤ 0.10%; total impurities ≤ 0.50%
Water content≤ 0.5% (Karl Fischer)
Heavy metals≤ 20 ppm (ICP-MS)
PolymorphForm I confirmed by XRD
Residual solventsComplies with ICH Q3C Option 1

Application

Injectable and oral NSAID for cattle, swine, horses and companion animals.

Packaging, storage & logistics

Standard packaging1 kg / 5 kg aluminium-laminated foil bag in fibre drum
Minimum order10 kg
Lead time20–30 days
Storage conditionsStore below 25 °C, protected from light
Shipping documentsInvoice, packing list, CoA, SDS, certificate of origin; DGM/IATA declaration where applicable

Pack sizes available — pick one to prefill the enquiry

100 g1 kg5 kg25 kg

Documentation provided

  • CoA per batchBatch-specific, tested against the specification agreed at PO stage
  • SDSCurrent GHS revision; destination-language version on request
  • MRL guidance noteMaximum residue limit and withdrawal-period reference for the destination market

Need the DMF open part, a sample CoA or an audit pack before you can qualify us? Ask on the enquiry form — we send those documents before any commercial discussion.

Request a quotation

Submitting opens your email client with these details filled in, so the enquiry reaches gm@bioranpharma.com directly. We use your details only to answer this enquiry — see privacy & data use.

Related products